



INFORMATION DISCLOSURE CITATION	Docket No.: RLL-459US	Serial No.: 10/593,939
	Applicants: CHUGH <i>et al.</i>	
	Filed: 2/25/2006	Group: 1617

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,377,584	3/22/1983	Rasmusson <i>et al.</i>	424	258	
	A2	4,760,071	7/26/1988	Rasmusson <i>et al.</i>	514	284	
	A3	5,017,568	5/21/1991	Holt <i>et al.</i>	514	173	
	A4	5,096,890	3/17/1992	Cross <i>et al.</i>	514	422	
	A5	5,155,107	10/13/1992	Panzeri <i>et al.</i>	514	232.8	
	A6	5,233,053	8/3/1993	Cross <i>et al.</i>	548	568	
	A7	5,403,847	4/4/1995	Gluchowski <i>et al.</i>	514	318	
	A8	5,565,467	10/15/1996	Batchelor <i>et al.</i>	514	284	
	A9	5,578,611	11/26/1996	Gluchowski <i>et al.</i>	514	318	
	A10	5,595,985	1/21/1997	Labrie	514	169	
	A11	5,780,485	7/14/1998	Gluchowski <i>et al.</i>	514	318	
	A12	5,990,128	11/23/1999	Gluchowski <i>et al.</i>	514	318	
	A13	6,015,819	1/18/2000	Gluchowski <i>et al.</i>	514	318	
	A14	6,274,583	8/14/2001	Patane <i>et al.</i>	514	255	
	A15	6,376,503	4/23/2002	Patane <i>et al.</i>	514	274	
	A16	6,410,554	6/25/2002	Broten <i>et al.</i>	514	299	
	A17	6,423,719	7/23/2002	Lawyer	514	263	
	A18	2001/0044438	11/22/2001	Wyllie	514	252.17	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	B1	EP 0 325 571	7/26/1989	EPO	C07C	215/54		
	B2	EP 0 388 054	9/19/1990	EPO	C07D	207/08		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-459US

Serial No.: 10/593,939

Applicants: CHUGH *et al.*

Filed: 2/25/2006

Group: 1617

	B3	EP 0 572 165	12/1/1993	EPO	C07J	73/00	
	B4	EP 0 572 166	12/1/1993	EPO	C07J	73/00	
	B5	EP 0 801 067	10/15/1997	EPO	C07D	453/02	
	B6	EP 1 123 705	8/16/2001	EPO	A61K	31/505	
	B7	GB 940,540	10/30/1963	UK	C07C		
	B8	WO 93/23038	11/25/1993	PCT	A61K	31/435	
	B9	WO 93/23039	11/25/1993	PCT	A61K	31/435	
	B10	WO 93/23040	11/25/1993	PCT	A61K	31/435	
	B11	WO 93/23041	11/25/1993	PCT	A61K	31/435	
	B12	WO 93/23048	11/25/1993	PCT	A61K	31/45	
	B13	WO 93/23050	11/25/1993	PCT	A61K	31/495	
	B14	WO 93/23051	11/25/1993	PCT	A61K	31/495	
	B15	WO 93/23376	11/25/1993	PCT	C07D	215/00	
	B16	WO 93/23419	11/25/1993	PCT	C07J	73/00	
	B17	WO 93/23420	11/25/1993	PCT	C07J	73/00	
	B18	WO 96/40136	12/19/1996	PCT	A61K	31/445	
	B19	WO 98/05641	2/12/1998	PCT	C07D	211/46	
	B20	WO 98/57638	12/23/1998	PCT	A61K	31/445	
	B21	WO 99/57131	11/11/1999	PCT	C07H	21/04	
	B22	WO 01/21167	3/29/2001	PCT	A61K	31/13	
	B23	WO 02/44151	6/6/2002	PCT	C07D	209/48	
	B24	WO 03/084928	10/16/2003	PCT	C07D	209/48	
	B25	WO 2004/004629	1/15/2004	PCT	A61K		
	B26	WO 2004/014853	2/19/2004	PCT	C07D	209/02	
	B27	WO 2004/018422	3/4/2004	PCT	C07D	209/52	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-459US	Serial No.: 10/593,939
	Applicants: CHUGH <i>et al.</i>	
	Filed: 2/25/2006	Group: 1617

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C1	Berry et al., "The development of Human Benign Prostatic Hyperplasia With Age", <i>The Journal of Urology</i> , 132:474-479 (1984)	
C2	Speakman, "Initial Choices and Final Outcomes in Lower Urinary Tract Symptoms", <i>European Urology</i> , 40(Suppl. 4):21-30 (2001)	
C3	Shapiro et al., "The Relative Proportion of Stromal and Epithelial Hyperplasia is Related to the Development of Symptomatic Benign Prostate Hyperplasia", <i>The Journal of Urology</i> , 147:1293-1297 (1992)	
C4	Caine, "The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy", <i>The Journal of Urology</i> , 136:1-4 (1986)	
C5	Andersson, "Mode of action of α_1 -adrenoreceptor antagonists in the treatment of lower urinary tract symptoms", <i>BJU International</i> , 85(Suppl. 2):12-18 (2000)	
C6	Wilde and Goa, "Finasteride: An Update of its Use in the Management of Symptomatic Benign Prostatic Hyperplasia", <i>Drugs</i> , 57(4):557-581 (1999)	
C7	Chapple, " α -adrenergic blocking drugs in bladder outflow obstruction: what potential has α_1 -adrenoceptor selectivity?", <i>British Journal of Urology</i> , 76(Suppl. 1):47-55 (1995)	
C8	Kawabe and Nijima, "Use of an α_1 -Blocker, YM-12617, in Micturition Difficulty", <i>Urologia Internationalis</i> , 42:280-284 (1987)	
C9	Lepor et al., "A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia", <i>The Journal of Urology</i> , 148:1467-1474 (1992)	
C10	Reuther and Aagaard, " α -Adrenergic Blockade in the Diagnosis of Detrusor Instability Secondary to Infravesical Obstruction", <i>Urologia Internationalis</i> , 39:312-313 (1984)	
C11	Serels and Stein, "Prospective Study Comparing Hyoscyamine, Doxazosin, and Combination Therapy for the Treatment of Urgency and Frequency in Women", <i>Neurourology and Urodynamics</i> , 17(1):31-36 (1998)	
C12	Schwinn et al., "Cloning and Pharmacological Characterization of Human Alpha-1 Adrenergic Receptors: Sequence Corrections and Direct Comparison with Other Species Homologues", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 272(1):134-142 (1995)	
C13	Hieble et al., "International Union of Pharmacology X. Recommendation for Nomenclature of α_1 -Adrenoceptors: Consensus Update", <i>Pharmacological Reviews</i> , 47(2):267-270 (1995)	
C14	Goepel et al., "Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate", <i>Urological Research</i> , 25(3):199-206 (1997)	
C15	Hieble et al., "In vitro characterization of the α -adrenoceptors in human prostate", <i>European Journal of Pharmacology</i> , 107(2):111-117 (1985)	
C16	Chapple et al., "Characterisation of Human Prostatic Adrenoceptors using Pharmacology Receptor Binding and Localisation", <i>British Journal of Urology</i> , 63:487-496 (1989)	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-459US

Serial No.: 10/593,939

Applicants: CHUGH *et al.*

Filed: 2/25/2006

Group: 1617

C17

Price et al., "Identification, Quantification, and Localization of mRNA for Three Distinct Alpha₁ Adrenergic Receptor Subtypes in Human Prostate", *The Journal of Urology*, 150:546-551 (1993)

C18

Forray et al., "The α_1 -Adrenergic Receptor that Mediates Smooth Muscle Contraction in Human Prostate Has the Pharmacological Properties of the Cloned Human α_{1C} Subtype", *Molecular Pharmacology*, 45:703-708 (1994)

C19

Lepor et al., "A Comparison of the Binding and Functional Properties of Alpha-1 Adrenoceptors and Area Density of Smooth Muscle in the Human, Canine and Rat Prostates", *The Journal of Pharmacology and Experimental Therapeutics*, 270(2):722-727 (1994)

C20

Muramatsu et al., "Pharmacological characterization of α_1 -adrenoceptor subtypes in the human prostate: functional and binding studies", *British Journal of Urology*, 74:572-578, (1994)

C21

Daniels et al., "Human cloned α_{1A} -adrenoceptor isoforms display α_{1L} -adrenoceptor pharmacology in functional studies", *European Journal of Pharmacology*, 370:337-343 (1999)

C22

Oesterling, "The Origin and Development of Benign Prostatic Hyperplasia An Age-Dependent Process", *Journal of Andrology*, 12(6):348-355 (1991)

C23

Michel, "Potential Role of α_1 -Adrenoceptors in the Aetiology of LUTS", *European Urology Supplements*, 1(9):5-13 (2002)

C24

Hieble and Ruffolo, Jr., "Recent advances in the identification of α_1 - and α_2 -adrenoceptor subtypes: therapeutic implications", *Expert Opinion on Investigational Drugs*, 6(4):367-387 (1997)

C25

Young et al., "Congenital obstruction of the posterior urethra", *The Journal of Urology*, 167:265-267 (2002)

C26

Staskin et al., "Overview Consensus Statement", *Urology*, 60(Suppl. 5A):1-6 (2002)

C27

Caulfield and Birdsall, "International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors", *Pharmacological Reviews*, 50(2):279-290 (1998)

C28

Hegde and Eglen, "Muscarinic Receptor Subtypes Modulating Smooth Muscle Contractility in the Urinary Bladder", *Life Sciences*, 64(6/7):419-428 (1999)

C29

Fetscher et al., "M₃ muscarinic receptors mediate contraction of human urinary bladder", *British Journal of Pharmacology*, 136(5):641-644 (2002)

C30

Yamanishi et al., "Which muscarinic receptor is important in the bladder?", *World Journal of Urology*, 19(5):299-306 (2001)

C31

Sullivan and Abrams, "Pharmacological Management of Incontinence", *European Urology*, 36(Suppl. 1):89-95 (1999)

C32

Lozewicz, "Bladder outflow obstruction induced by ipratropium bromide", *Postgraduate Medical Journal*, 65(762):260-261 (1989)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-459US	Serial No.: 10/593,939
	Applicants: CHUGH <i>et al.</i>	
	Filed: 2/25/2006	Group: 1617

	C33	Abrams et al., "Safety of tolterodine in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity", <i>European Urology Supplements</i> , <u>1</u> :132, Abstract 520 (2002)
	C34	Bundgaard, H. (ed.). (1995). <i>Design of Prodrugs</i> . Elsevier.
	C35	Michel et al., "Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned α_1 -adrenoceptor subtypes and in human prostate", <i>Journal of Autonomic Pharmacology</i> , <u>16</u> :21-28 (1996)
	C36	Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", <i>Life Sciences</i> , <u>64</u> (25):2351-2358 (1999)
	C37	Jeppesen et al., "1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.0 ^{2,6}]heptanes as New Potent Muscarinic M ₁ Agonists: Structure-Activity Relationship for 3-Aryl-2-propyn-1-yloxy and 3-Aryl-2-propyn-1-ylthio Derivatives", <i>Journal of Medicinal Chemistry</i> , <u>42</u> (11):1999-2006 (1999)
	C38	Kenny et al., "Pharmacological Options in the Treatment of Benign Prostatic Hyperplasia," <i>Journal of Medicinal Chemistry</i> , <u>40</u> (9):1293-1315 (1997)
	C39	Athanasopoulos et al., "Combination Treatment with an α -Blocker Plus an Anticholinergic for Bladder Outlet Obstruction: A Prospective, Randomized, Controlled Study", <i>The Journal of Urology</i> , <u>169</u> :2253-2256 (2003)
	C40	Ranjan et al., "Comparative study of human steroid 5 α -reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride", <i>Life Sciences</i> , <u>71</u> (2):115-126 (2002)
	C41	Andriole and Kirby, "Safety and Tolerability of the Dual 5 α -Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic Hyperplasia", <i>European Urology</i> , <u>44</u> (1):82-88 (2003)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	